Accordingly, during the response to targeted therapy, the BRAF-mutant allele fraction, detectable in the cell-free circulating tumor DNA (ctDNA) at the start of treatment (MAF of 0.64%), became undetectable. This evidence concerns the gene BRAF and neoplasm.